A repurposed cancer drug is showing encouraging results in Alzheimer’s trial

In a recent paper published in the journal Annals of Neurology, it is reporting encouraging results from a small Phase 2 human trial testing the effects of a cancer drug in treating Alzheimer’s disease.  The principal investigator on this new study from Georgetown University Medical Center, R. Scott Turner, points out the goal of this initial trial was only to establish safety, tolerability and the pharmacokinetics of nilotinib in Alzheimer’s disease patients.  However, it is still early days; an Alzheimer’s research is particularly notorious in delivering promising early-stage data only to fail in later-stage trialing. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org